Santa Fe Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Santa Fe Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,051	Closed	-$391K	–	350
2015 Q4	$391K	Sell	2,051 -22,778	-92%	-$3.98M	0.06%	368
2015 Q3	$3.88M	Buy	+24,829	New	+$4.53M	0.52%	1
2015 Q2	–	Sell	-21,704	Closed	-$3.76M	–	623
2015 Q1	$3.76M	Buy	+21,704	New	+$3.93M	0.46%	53
2014 Q4	–	Sell	-17,611	Closed	-$2.92M	–	623
2014 Q3	$2.92M	Sell	17,611 -3,921	-18%	-$644K	0.45%	56
2014 Q2	$3.37M	Buy	+21,532	New	+$3.4M	0.5%	19
2014 Q1	–	Sell	-12,746	Closed	-$1.69M	–	603
2013 Q4	$1.69M	Buy	+12,746	New	+$1.53M	0.28%	153
2013 Q3	–	Sell	-10,218	Closed	-$942K	–	620
2013 Q2	$942K	Buy	+10,218	New	+$985K	0.19%	213

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Santa Fe Partners's ALXN Position: Q1 2016 in Review

Santa Fe Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 2,051 shares — an estimated $391K sold.

Santa Fe Partners first reported a position in ALXN in Q2 2013 and held it in 7 quarters. The position peaked at $3.88M in Q3 2015. 518 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

Santa Fe Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Santa Fe Partners sold 2,051 Alexion Pharmaceuticals shares in Q1 2016, an estimated $391K.
Santa Fe Partners first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Santa Fe Partners's Alexion Pharmaceuticals position peaked at $3.88M in Q3 2015.
518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Santa Fe Partners's 13F filing for Q1 2016.